Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Read more about Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Agios Announces Pricing of $256 Million Public Offering of Common Stock Read more about Agios Announces Pricing of $256 Million Public Offering of Common Stock
Agios Announces Proposed Offering of Common Stock Read more about Agios Announces Proposed Offering of Common Stock
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting Read more about Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting
Agios Reports Business Highlights and Third Quarter 2019 Financial Results Read more about Agios Reports Business Highlights and Third Quarter 2019 Financial Results
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors Read more about Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019 Read more about Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019
Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference Read more about Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference
Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients Read more about Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients
Q3 2019 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q3 2019 Agios Pharmaceuticals Inc Earnings Conference Call